Serum albumin-adjusted glycated albumin is a better indicator of glycaemic control in diabetic patients with end-stage renal disease not on haemodialysis

被引:14
|
作者
Fukami, Kei [1 ]
Shibata, Ryo [1 ]
Nakayama, Hitomi [2 ]
Yamada, Kentaro [2 ]
Okuda, Seiya [1 ]
Koga, Masafumi [3 ]
机构
[1] Kurume Univ, Sch Med, Dept Med, Div Nephrol, Kurume, Fukuoka 830, Japan
[2] Kurume Univ, Sch Med, Dept Med, Div Endocrinol & Metab, Kurume, Fukuoka 830, Japan
[3] Kawanishi City Hosp, Dept Internal Med, Kawanishi, Hyogo 6660195, Japan
关键词
Diabetic nephropathy; glycated albumin; HbA1c; end-stage renal disease; serum albumin; PLASMA-GLUCOSE; HEMOGLOBIN; COMPLICATIONS; VALUES; DEATH;
D O I
10.1177/0004563214568162
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Backgrounds Diabetic patients with end-stage renal disease who are not on haemodialysis show low concentrations of HbA1c and glycated albumin due to renal anaemia and proteinuria, respectively. In the present study, we examined whether serum albumin-adjusted glycated albumin could accurately reflect glycaemic control in these patients. Methods To examine the correlation between glycated albumin and serum albumin (Study 1), 49 diabetic patients with end-stage renal disease not on haemodialysis were used. To evaluate the association between the glycaemic control indicators and the glycaemic control state (Study 2), 30 diabetic patients with end-stage renal disease were enrolled. The estimated HbA1c and the estimated glycated albumin concentrations were calculated based on the mean blood glucose concentrations obtained from the diurnal variation. The adjusted glycated albumin concentrations were calculated from the regression formula between the serum albumin and glycated albumin obtained from Study 1. Results No significant correlation was found between the measured HbA1c and estimated HbA1c concentrations. The estimated HbA1c (inversely) and measured HbA1c/estimated HbA1c ratio (positively), but not measured HbA1c, showed a significant correlation with Hb concentrations. The estimated glycated albumin was positively associated with the measured glycated albumin and adjusted glycated albumin concentrations. Although measured glycated albumin/estimated glycated albumin ratio was positively correlated with serum albumin, there was no significant association between the adjusted glycated albumin/estimated glycated albumin ratio and serum albumin, Hb and estimated glomerular filtration rate. Conclusions We found for the first time that the adjustment of glycated albumin by serum albumin could be useful to determine glycaemic control in diabetic patients with end-stage renal disease not on haemodialysis. These findings suggest that adjusted glycated albumin might be a better indicator of glycaemic control than measured HbA1c and measured glycated albumin in these patients.
引用
收藏
页码:488 / 496
页数:9
相关论文
共 50 条
  • [41] Anakinra for Refractory Pseudogout in Patients with End-stage Renal Disease on Haemodialysis
    Antoniadou, Christina
    Fytanidis, Nikolaos
    Devetzis, Vasileios
    Kantartzi, Konstantia
    Papagoras, Charalampos
    MEDITERRANEAN JOURNAL OF RHEUMATOLOGY, 2024, 35 (01):
  • [42] Pharmacokinetics of Aliskiren in Patients with End-Stage Renal Disease Undergoing Haemodialysis
    Khadzhynov, Dmytro
    Slowinski, Torsten
    Lieker, Ina
    Neumayer, Hans-Hellmut
    Albrecht, Diego
    Streefkerk, Henk Johan
    Rebello, Sam
    Peters, Harm
    CLINICAL PHARMACOKINETICS, 2012, 51 (10) : 661 - 669
  • [43] The impact of glycaemic control on outcomes in patients with end-stage renal disease and type 2 diabetes
    Zoungas, Sophia
    Kerr, Peter G.
    Lui, Michelle
    Teede, Helena J.
    NEPHROLOGY, 2008, 13 (02) : 124 - 127
  • [44] POST-PARATHYROIDECTOMY STATE AND SERUM ALBUMIN LEVELS IN END-STAGE RENAL DISEASE PATIENTS: NO APPARENT EFFECT OF SURGICAL PARATHYRODECTOMY
    Clarke, David R.
    Musa, Abdeen R. Farah
    Fuelop, Tibor
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2015, 65 (04) : A28 - A28
  • [45] Albumin dialysis using the MARS® system in the treatment of patients with end-stage liver disease and renal failure
    Saliba, F.
    Ichai, P.
    Belnard, M.
    Azoulay, D.
    Adam, R.
    Castaing, D.
    Samuel, D.
    JOURNAL OF HEPATOLOGY, 2006, 44 : S68 - S68
  • [46] Cardiovascular risk in diabetic end-stage renal disease patients
    Wang, Angela Yee-Moon
    JOURNAL OF DIABETES, 2011, 3 (02) : 119 - 131
  • [47] Prognostic value of C-reactive protein/albumin ratio for cardiovascular morbidity and mortality in end-stage renal disease patients with incident haemodialysis therapy
    Takahashi, H.
    Ishii, H.
    Kumada, Y.
    Oshima, T.
    Sakakibara, T.
    Ito, R.
    Murohara, T.
    Ozaki, Y.
    EUROPEAN HEART JOURNAL, 2019, 40 : 885 - 885
  • [48] Effect of Sevelamer and Nicotinamide on Albumin Carbamylation in Patients with End-Stage Kidney Disease
    Lenglet, Aurelie
    Rahali, Mohamad Ali
    Sauvage, Francois-Ludovic
    Liabeuf, Sophie
    Choukroun, Gabriel
    Essig, Marie
    El Balkhi, Souleiman
    Massy, Ziad A.
    DRUGS IN R&D, 2021, 21 (02) : 231 - 238
  • [49] Effect of Sevelamer and Nicotinamide on Albumin Carbamylation in Patients with End-Stage Kidney Disease
    Aurelie Lenglet
    Mohamad Ali Rahali
    François-Ludovic Sauvage
    Sophie Liabeuf
    Gabriel Choukroun
    Marie Essig
    Souleiman El Balkhi
    Ziad A. Massy
    Drugs in R&D, 2021, 21 : 231 - 238
  • [50] YKL-40 in patients with end-stage renal disease receiving haemodialysis
    Nielsen, Ture Lange
    Plesner, Louis Lind
    Warming, Peder Emil
    Pallisgaard, Jannik Langtved
    Dalsgaard, Morten
    Schou, Morten
    Host, Ulla
    Rydahl, Casper
    Brandi, Lisbet
    Kober, Lars
    Johansen, Julia Sidenius
    Kastrup, Jens
    Iversen, Kasper Karmark
    BIOMARKERS, 2018, 23 (04) : 357 - 363